About Us

The company was established in 2009 in Vienna, Austria as a biotech consulting firm. It was later rebranded as Capricorn Consilium GmbH (Ltd.). Since mid-2017, Capricorn Consilium has been working on vaccine projects, a shift prompted by the addition of Prof. Dr. A. Egorov to the team.

​

In 2023, the company was acquired and fully restructured by new owners, who introduced numerous innovative technologies for vaccine development from Capricorn's sister companies. A new management board was appointed, and the company was renamed Capricorn Technologies GmbH.

​

Since 2018, Capricorn has developed and accumulated various inventions and expertise, including methods for constructing safe influenza vectors, a high-throughput clone of the Vero cell line, and an effective method for purifying vaccine candidates. Experimental samples of a universal influenza vaccine and a circovirus vaccine for pigs have also been developed. Convincing evidence of the safety and immunogenicity of these drugs has been obtained when administered intranasally to 8-week-old piglets. Ongoing studies are investigating the effectiveness of veterinary vaccines when administered intradermally.